Home | About IPJ | Editorial board | Ahead of print | Current Issue | Archives | Instructions | Contact us |   Login 
Industrial Psychiatry Journal
Search Articles   
    
Advanced search   
 


 
SHORT COMMUNICATION
Year : 2022  |  Volume : 31  |  Issue : 2  |  Page : 370-373  Table of Contents     

Adding pre-emptive anticholinergics to antipsychotics: Is it justified?


1 Department of Psychiatry, Armed Forces Medical College, Pune, Maharashtra, India
2 Department of Psychiatry, Base Hospital, Tezpur, Assam, India

Date of Submission27-Dec-2021
Date of Acceptance18-Jun-2022
Date of Web Publication30-Aug-2022

Correspondence Address:
Dr. Ankit Dangi
Department of Psychiatry, Armed Forces Medical College, Pune - 411 040, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ipj.ipj_269_21

Rights and Permissions
   Abstract 


Anti-psychotics are the mainstay of treatment for Schizophrenia and psychotic disorders. Historically, anticholinergics have been prescribed to prevent or treat extrapyramidal side effects (EPS) associated with first-generation antipsychotics (FGAs). Even though newer antipsychotics are associated with markedly lower rates of EPS, concurrent anticholinergic use remains high. Use of these medications has potential for long-term side effects, worsening of EPS and poor adherence. We have briefly discussed the limited association between second-generation antipsychotics (SGAs) and EPS, the efficacy of anticholinergics for different types of EPS, and summarized various national and international guidelines on the subject. In conclusion, there is no evidence for prophylactic use of anticholinergics with antipsychotics. Clinicians need to guard against this tendency to be unduly cautious.

Keywords: Anticholinergics, antipsychotics, extrapyramidal symptoms, prophylaxis


How to cite this article:
Chatterjee K, Dangi A, Sharma R, Yadav P, Chauhan VS, Prakash J. Adding pre-emptive anticholinergics to antipsychotics: Is it justified?. Ind Psychiatry J 2022;31:370-3

How to cite this URL:
Chatterjee K, Dangi A, Sharma R, Yadav P, Chauhan VS, Prakash J. Adding pre-emptive anticholinergics to antipsychotics: Is it justified?. Ind Psychiatry J [serial online] 2022 [cited 2022 Dec 2];31:370-3. Available from: https://www.industrialpsychiatry.org/text.asp?2022/31/2/370/355059



Psychotic disorders are common debilitating disorders associated with disturbances in perception, emotion and thought. In India, 0.4% of the population is believed to suffer from schizophrenia and other psychotic disorders.[1] Antipsychotics are the mainstay of treatment for these disorders.[2] The discovery of Chlorpromazine in 1952 for treatment of psychotic disorders was the major landmark in the history of drug treatment in psychiatry.[3] This was followed by discovery of various other drugs effective for treatment of psychosis. These drugs, however, had a common adverse effect of extrapyramidal symptoms (EPS). These symptoms include acute dyskinesia, acute dystonia, akathisia, tardive dyskinesia, drug-induced Parkinsonism and neuroleptic malignant syndrome (NMS) (shown in [Table 1]).[4],[5] At one stage, the development of EPS was considered essential for antipsychotic action. However, introduction of Clozapine in European markets in early 1970s laid these claims to rest.[6] A whole generation of antipsychotics developed after this were associated with significantly lower rates of EPS. This was considered a major advance in the field of psychopharmacology with claims of superiority in terms of effectiveness and reduced side effects, combining serotonin and dopamine antagonism.[7] These drugs include Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole etc.[8] Clinical observation and research evidence has found significant differences between second-generation antipsychotics (SGAs) as a drug class in terms of EPS.[9]
Table 1: Extrapyramidal symptoms (EPS) caused by antipsychotic medications

Click here to view


Despite this, many clinicians routinely use anticholinergics prophylactically with antipsychotics. One study from Bahrain found that almost two thirds of patients were prescribed anticholinergics along with antipsychotics.[10] This is despite distressing adverse effects associated with anticholinergics like dry mouth, urinary disturbances, constipation, cognitive impairment, worsening of tardive dyskinesia and delirium.[11] This paper aims to explore the rationale for prophylactic use of anticholinergics with antipsychotics. We review the scientific literature for such use and summarize the major practice guidelines on the subject.

Why are anticholinergics prescribed with antipsychotics?

Anticholinergics are prescribed ostensibly for treatment or prophylaxis of EPS induced by antipsychotics. Of these symptoms, acute dystonia and akathisia develop within hours of initiation of antipsychotic medications. Drug-induced Parkinsonism develops over weeks, while Tardive Dyskinesia takes months to years to develop.

Acute dystonic reactions are effectively treated with anticholinergic drugs. Symptom resolution is dramatic within 10 to 30 min of administration of parenteral anticholinergics.[12] A Cochrane review conducted in 2006 found that there was no reliable data to recommend or refute the use of anticholinergics in neuroleptic-induced akathisia.[13] A systematic review on treatment considerations for antipsychotic-induced akathisia reported that before considering adjuvant medications for treatment one must consider dose reduction and cessation or switching of the antipsychotic.[14] It further added that considering the limitations of the available evidence on anticholinergic medications and the risk of cognitive and anticholinergic adverse effects with these drugs, anticholinergic medications should not be routinely used for the treatment of akathisia.[14] A Cochrane review conducted in 2018 reported that it was uncertain that the use of anticholinergics is useful in patients with tardive dyskinesia.[15] A review of literature also suggests that anticholinergics should be avoided in dyskinesia as they can likely worsen the symptoms.[16] Literature also suggests that anticholinergics may be efficacious in treatment of drug-induced parkinsonism; however, it recommends that use should be short-term particularly in elderly.[16],[17]

Do SGAs cause significant EPS?

Extra Pyramidal Symptoms are common side effects of most FGAs. EPS also occur with SGAs, although in significantly reduced rates as reported in a meta-analysis of efficacy and safety of FGAs vs. SGAs. In this meta-analysis, pooled SGAs produced significantly less EPS compared to FGAs (effect size of –0.43, P < 0.001).[18] A number of predisposing factors have been identified for this increased risk like high-dose antipsychotic use, a past history of extrapyramidal symptoms and medical comorbidity. In comparative studies of FGAs and SGAs, the choice of a first-generation comparator significantly influences the results.[19] Within SGAs also, a spectrum of propensity to cause EPS has been found. Lurasidone and Risperidone on one end of the spectrum cause more EPS, while Clozapine on the other has least EPS causing potential.[2],[20] EPS causing potential of different SGAs correlate with their D2 antagonism [Figure 1].[19] One Cochrane meta-analysis reported highest rates of movement disorders with L-sulpiride among SGAs. In the same study, Quetiapine (1.4%) and Olanzapine (1.6%) had lowest prevalence estimate of dystonia.[21]
Figure 1: D2 receptor binding affinity of selected antipsychotics in terms of inhibition coefficient (Ki). Low Ki values indicate higher binding affinity and thus chances of EPS.[22]

Click here to view


Available Recommendations regarding use of anticholinergics with antipsychotics

A number of clinical guidelines based on sound scientific evidence are available to guide clinicians in their management of patients with Schizophrenia and other psychotic disorders. These guidelines also talk about management of any treatment emergent adverse effects. Important clinical practice guidelines include those from British Association of Psychopharmacology, Schizophrenia Patient Outcome Research Team (PORT), American Psychiatric Association (APA), Indian Psychiatric Society (IPS), and World Federation of Association of Biological Psychiatry (WFSBP).

The salient factors regarding the use of anticholinergics with antipsychotics are highlighted [Table 2].
Table 2: Salient factors from guidelines regarding use of anticholinergics with antipsychotics

Click here to view



   Conclusion Top


There exists no scientific rationale for preemptively prescribing anticholinergics with antipsychotics. Despite existing evidence-based guidelines advocating against prophylactic use of anticholinergics with antipsychotics, such use remains rampant. Many patients remain on these medications over long periods, which is not rational. This nonjudicious use has implications in terms of increased central and peripheral anticholinergic side effects, possible worsening of extrapyramidal symptoms and nonadherence with medications. There is a need for the clinicians to guard against the tendency to add anticholinergics as a routine. A considered decision to start anticholinergics should be taken for emergent EPS which respond to such medication and for the shortest duration possible. We strongly recommend against preemptive adding of anticholinergic medications, while prescribing SGAs.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Sagar R, Dandona R, Gururaj G, Dhaliwal RS, Singh A, Ferrari A, et al. The burden of mental disorders across the states of India: The Global burden of disease study 1990–2017. Lancet Psychiatry 2020;7:148-61.  Back to cited text no. 1
    
2.
Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 2013;382:951-62.  Back to cited text no. 2
    
3.
Ramachandraiah CT, Subramaniam N, Tancer M. The story of antipsychotics: Past and present. Indian J Psychiatry 2009;51:324.  Back to cited text no. 3
[PUBMED]  [Full text]  
4.
Blair DT, Dauner A. Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs. Nurse Pract 1992;17:56, 62-4, 67.  Back to cited text no. 4
    
5.
Berman BD. Neuroleptic malignant syndrome. Neurohospitalist 2011;1:41-7.  Back to cited text no. 5
    
6.
Crilly J. The history of clozapine and its emergence in the US market: A review and analysis. Hist Psychiatry 2007;18:39-60.  Back to cited text no. 6
    
7.
Carpenter WT, Davis JM. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatry 2012;17:1168-73.  Back to cited text no. 7
    
8.
Association AD. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.  Back to cited text no. 8
    
9.
Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: A systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012;38:167-77.  Back to cited text no. 9
    
10.
Khaja KAJA, Al-Haddad MK, Sequeira RP, Al-Offi AR. Antipsychotic and anticholinergic drug prescribing pattern in psychiatry: Extent of evidence-based practice in Bahrain. Pharmacol Amp Pharm 2012;3:409-16.  Back to cited text no. 10
    
11.
Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. Psychiatry Clin Neurosci 2014;68:37-49.  Back to cited text no. 11
    
12.
van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999;319:623-6.  Back to cited text no. 12
    
13.
Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2006;2006:CD003727.  Back to cited text no. 13
    
14.
Pringsheim T, Gardner D, Addington D, Martino D, Morgante F, Ricciardi L, et al. The assessment and treatment of antipsychotic-induced Akathisia. Can J Psychiatry 2018;63:719-29.  Back to cited text no. 14
    
15.
Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018;2018:CD000204.  Back to cited text no. 15
    
16.
Ritchie CW. Drug-induced parkinsonism and abnormal involuntary movements. Psychiatry Park Dis 2012;27:133-44.  Back to cited text no. 16
    
17.
Shin H-W, Chung SJ. Drug-induced Parkinsonism. J Clin Neurol Seoul Korea 2012;8:15-21.  Back to cited text no. 17
    
18.
Zhang J-P, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs first-generation antipsychotics in first episode psychosis: A systematic review and meta-analysis. Int J Neuropsychopharmacol 2013;16:1205-18.  Back to cited text no. 18
    
19.
Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Res Int 2014;2014:e656370.  Back to cited text no. 19
    
20.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 2019;394:939-51.  Back to cited text no. 20
    
21.
Martino D, Karnik V, Osland S, Barnes TRE, Pringsheim TM. Movement disorders associated with antipsychotic medication in people with schizophrenia: An overview of cochrane reviews and meta-analysis. Can J Psychiatry 2018;63:730-9.  Back to cited text no. 21
    
22.
Kwak YT, Yang Y, Jang H. Understanding of antipsychotics in elderly patients with dementia. Dement Neurocognitive Disord 2015;14:53-69.  Back to cited text no. 22
    
23.
Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxf) 2020;34:3-78.  Back to cited text no. 23
    
24.
Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2020;177:868-72.  Back to cited text no. 24
    
25.
Grover S, Chakrabarti S, Kulhara P, Avasthi A. Clinical practice guidelines for management of schizophrenia. Indian J Psychiatry 2017;59(Suppl 1):S19.  Back to cited text no. 25
    
26.
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller H-J, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132-91.  Back to cited text no. 26
    
27.
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The schizophrenia patient outcomes research team (PORT): Updated treatment recommendations 2009. Schizophr Bull 2010;36:94-103.  Back to cited text no. 27
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
  
 
  Search
 
  
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed2691    
    Printed31    
    Emailed0    
    PDF Downloaded50    
    Comments [Add]    

Recommend this journal